文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2022.

作者信息

Ditsch Nina, Wöcke Achim, Untch Michael, Jackisch Christian, Albert Ute-Susann, Banys-Paluchowski Maggie, Bauerfeind Ingo, Blohmer Jens-Uwe, Budach Wilfried, Dall Peter, Fallenberg Eva Maria, Fasching Peter A, Fehm Tanja N, Friedrich Michael, Gerber Bernd, Gluz Oleg, Harbeck Nadia, Heil Jörg, Huober Jens, Kreipe Hans H, Krug David, Kühn Thorsten, Kümmel Sherko, Kolberg-Liedtke Cornelia, Loibl Sibylle, Lüftner Diana, Lux Michael Patrick, Maass Nicolai, Mundhenke Christoph, Nitz Ulrike, Park-Simon Tjoung-Won, Reimer Toralf, Rhiem Kerstin, Rody Achim, Schmidt Marcus, Schneeweiss Andreas, Schütz Florian, Sinn Hans-Peter, Solbach Christine, Solomayer Erich-Franz, Stickeler Elmar, Thomssen Christoph, Witzel Isabell, Müller Volkmar, Janni Wolfgang, Thill Marc

机构信息

Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum Augsburg, Augsburg, Germany.

Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum Würzburg, Würzburg, Germany.

出版信息

Breast Care (Basel). 2022 Aug;17(4):403-420. doi: 10.1159/000524879. Epub 2022 May 5.

DOI:10.1159/000524879
PMID:36156915
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9453658/
Abstract

INTRODUCTION: The AGO (Arbeitsgemeinschaft Gynäkologische Onkologie, German Gynecological Oncology Group) Task Force on Diagnosis and Treatment of Breast Cancer as an interdisciplinary team consists of specialists from gynecological oncology, pathology, diagnostic radiology, medical oncology, and radiation oncology with a special focus on breast cancer. METHODS: The updated evidence-based treatment recommendation 2022 for early breast cancer (EBC) and metastatic breast cancer of the AGO Task Force has been released. RESULTS AND CONCLUSION: This paper captures the update of EBC.

摘要

相似文献

[1]
AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2022.

Breast Care (Basel). 2022-8

[2]
Arbeitsgemeinschaft Gynäkologische Onkologie Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2023.

Breast Care (Basel). 2023-8

[3]
Arbeitsgemeinschaft Gynäkologische Onkologie Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2024.

Breast Care (Basel). 2024-6

[4]
AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2019.

Breast Care (Basel). 2019-8

[5]
Arbeitsgemeinschaft Gynäkologische Onkologie Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2024.

Breast Care (Basel). 2024-6

[6]
AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2022.

Breast Care (Basel). 2022-8

[7]
AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2023.

Breast Care (Basel). 2023-8

[8]
German Recommendations for Diagnosis and Treatment of Breast Cancer 2008. What is New from the Breast Commission of the German Gynaecological Oncology Working Group (AGO)?

Breast Care (Basel). 2008

[9]
Diagnosis, Therapy and Follow-up of Cervical Cancer. Guideline of the DGGG, DKG and DKH (S3-Level, AWMF Registry No. 032/033OL, May 2021) - Part 2 with Recommendations on Psycho-oncology, Rehabilitation, Follow-up, Recurrence, Palliative Therapy and Healthcare Facilities.

Geburtshilfe Frauenheilkd. 2022-2-11

[10]
Treatment of Early Breast Cancer: The 18th St. Gallen International Breast Cancer Consensus Conference against the Background of Current German Treatment Recommendations.

Geburtshilfe Frauenheilkd. 2023-9-12

引用本文的文献

[1]
Omission of anthracyclines from neoadjuvant chemotherapy for breast cancer: a population-based analysis.

Breast Cancer Res Treat. 2025-8-13

[2]
Adjuvant Targeted Treatment of Early Hormone Receptor-positive HER2-negative Breast Cancer: Olaparib, Abemaciclib or Ribociclib - Which One, How and For Whom?

Geburtshilfe Frauenheilkd. 2025-4-22

[3]
Oncological outcomes of breast cancer patients after planned IORT boost with low-kV x-rays-results of the TARGIT BQR prospective phase IV trial.

Strahlenther Onkol. 2025-5-19

[4]
Update Breast Cancer 2024 Part 2 - Patients with Early Stage Breast Cancer.

Geburtshilfe Frauenheilkd. 2025-5-15

[5]
Do We Need Anthracyclines for Elderly Patients with Triple-Negative Breast Cancer?

Breast Care (Basel). 2025-3-13

[6]
Impact of risk and lifestyle factors on therapy goals in the treatment of breast cancer and gynecological cancer patients with integrative medicine.

Arch Gynecol Obstet. 2025-6

[7]
Real-world utilization of aromatase inhibitors, tamoxifen, and ovarian function suppression in premenopausal patients with early hormone receptor-positive, HER2-negative breast cancer with increased recurrence risk.

Breast. 2025-6

[8]
Navigating the Uncertainty of B3 Breast Lesions: Diagnostic Challenges and Evolving Management Strategies.

J Pers Med. 2025-1-18

[9]
Comparative assessment of breast volume using a smartphone device versus MRI.

Breast Cancer. 2025-1

[10]
Prognosis prediction with the IHC3 score in patients with node-negative, hormone receptor-positive, HER2-negative early breast cancer.

ESMO Open. 2024-11

本文引用的文献

[1]
Platinum is essential in neoadjuvant treatment of triple-negative breast cancer: a network meta-analysis.

Cancer Biol Med. 2022-2-16

[2]
Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer.

N Engl J Med. 2022-2-10

[3]
Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials.

Lancet Oncol. 2022-3

[4]
Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial.

Ann Oncol. 2022-4

[5]
Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: ASCO-OH (CCO) Guideline Update.

J Clin Oncol. 2022-3-1

[6]
Ductal Carcinoma in Situ: State-of-the-Art Review.

Radiology. 2022-2

[7]
Contrast-enhanced Mammography: A Systematic Review and Meta-Analysis of Diagnostic Performance.

Radiology. 2022-3

[8]
Prognostic Risk Assessment and Prediction of Radiotherapy Benefit for Women with Ductal Carcinoma In Situ (DCIS) of the Breast, in a Randomized Clinical Trial (SweDCIS).

Cancers (Basel). 2021-12-3

[9]
Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03).

J Clin Oncol. 2022-1-20

[10]
Contralateral breast cancer after curative-intent treatment for ductal carcinoma in situ: Rate and associated clinicopathological and imaging risk factors.

Clin Imaging. 2022-2

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索